Compare Adaptive Biotechnologies Corp (ADPT) vs Spotify Technology (SPOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Spotify Technology — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Spotify Technology trades at $485.53 (market cap $101.57B). The key difference: Spotify Technology is far larger — about 30.5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| ADPT | SPOT | |
|---|---|---|
Market Cap | $3.33B | $101.57B |
Sector | Health | Media |
52-Week High | $22.37 | $738.53 |
52-Week Low | $10.24 | $412.75 |
Enterprise Value | $3.19B | $92.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Spotify (SPOT) trades at $493.95, up 1.64% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth from $11.7B in 2022 to $17.2B in 2025 and net income turning positive to $2.2B. Analyst consensus is bullish with a $623 price target, supported by recent earnings beats. Key resistance is near $499, while support holds at $477.
Outlook remains positive driven by margin expansion and platform diversification, but risks include competition and market volatility. The stock offers growth potential with a 26% upside to consensus target, though investors should monitor execution on profitability goals amid rising content costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
